Duration of Trastuzumab with chemotherapy in women with early stage breast cancer: six months versus twelve.

Trial Profile

Duration of Trastuzumab with chemotherapy in women with early stage breast cancer: six months versus twelve.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Trastuzumab (Primary) ; Antineoplastics
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PERSEPHONE
  • Most Recent Events

    • 05 Jun 2018 Results assessing patient's perspective of living with and beyond the treatment of trastuzumab presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Primary endpoint has been met. (Disease-free survival) as per results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Status changed from to completed as per results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top